Safety of the extension of use of galacto-oligosaccharides as a novel food pursuant to Regulation (EU) 2015/2283
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the extension of use of galacto-oligosaccharides (GOS) as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is produced from milk-deriv...
| Autores: | , , , , , , , , , |
|---|---|
| Tipo de documento: | artigo |
| Estado: | Versão publicada |
| Data de publicação: | 2025 |
| País: | España |
| Recursos: | Universidad de Sevilla (US) |
| Repositório: | idUS. Depósito de Investigación de la Universidad de Sevilla |
| OAI Identifier: | oai:idus.us.es:11441/182720 |
| Acesso em linha: | https://hdl.handle.net/11441/182720 https://doi.org/10.2903/j.efsa.2025.9797 |
| Access Level: | Acceso aberto |
| Palavra-chave: | Extension of use Galacto-oligosaccharides GOS Novel food |
| Resumo: | Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the extension of use of galacto-oligosaccharides (GOS) as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is produced from milk-derived lactose using β-galactosidases. The applicant proposed to extend the use of GOS to several food categories (non-alcoholic beverages, confectionery, chewing gum, cocoa and chocolate-based products and protein products). The target population is the general population. GOS is already authorised and included in the Union list of NFs for use in several foods, including infant formula, and in food supplements. The Panel estimated that the proposed extension of use would result in a highest 95th percentile intake of GOS from all food uses, of up to 48.5 g/day in adults. As compared to the exposure to GOS from the currently authorised food uses (at the highest P95), the proposed extension of use is expected to result in an increase in intake of GOS of up to 17%. The information provided on the proposed use levels and anticipated intake does not raise safety concerns. The Panel concludes that the proposed extension of use of GOS is safe under the proposed conditions of use. |
|---|